Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: Orion Corporation, Orionintie 1, FI-02200, Espoo, Finland
First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.
Fareston is not recommended for patients with estrogen receptor negative tumours.
The recommended dose is 60 mg daily.
No dose adjustment is needed in patients with renal insufficiency.
Toremifene should be used cautiously in patients with liver impairment (see section 5.2).
There is no relevant use of Fareston in the paediatric population.
Toremifene is administered orally. Toremifene can be taken with or without food.
Vertigo, headache and dizziness were observed in healthy volunteer studies at daily dose of 680 mg. The dose-related QTc interval prolongation potential of Fareston should also be taken into account in cases of overdose. There is no specific antidote and the treatment is symptomatic.
3 years.
This medicinal product does not require any special storage conditions.
Green PVC foil and aluminium foil blister in a cardboard box.
Package sizes: 30 and 100 tablets.
Not all pack sizes may be marketed.
No special requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
